Content by Vall d'Hebron Institute of Oncology
|2 min read
Bendamustine Treatment before CAR T-Cell Therapy May Be Detrimental
CAR T-cell therapy recipients with refractory lymphoma showed poorer treatment outcomes when treated with bendamustine
|3 min read
VIGex Could Guide Patient Selection for Personalized Immunotherapy
Prediction tool classifies solid tumors based on inflammation status, thereby triaging cases that will benefit the most
|2 min read
Novel Protein Inhibitor Shows Antitumor Activity in Patients with NHL
Monotherapy with new PRMT5 inhibitor well tolerated with low toxicity in adults with B cell non-Hodgkin lymphomas
|2 min read
Pioneering Cell Therapies for Non-Responders to Current Immunotherapies
Killer T cells identified in blood that can hone in on mutations uniquely expressed in cancer cells pave the way for an alternative and personalized therapeutic avenuePage 1 of 1
